150
Participants
Start Date
June 30, 2016
Primary Completion Date
April 30, 2018
Study Completion Date
August 31, 2018
grazoprevir/elbasvir, ribavirin
To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
Behavioural Intervention
To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich
University of Zurich
OTHER